Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Dementia Discovery Fund

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 33
Average round size
The average size of a deal this fund participated in
Portfolio companies 21
Rounds per year 4.71
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Pharmaceutical

In 2015 was created Dementia Discovery Fund, which is appeared as VC. The main office of represented VC is situated in the London. The fund was located in Europe if to be more exact in United Kingdom.

The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Dementia Discovery Fund works on 12 percentage points less the average amount of lead investments.

Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Health Care, Life Science. Among the most popular portfolio startups of the fund, we may highlight Alector, MedaRed, Mitoconix Bio. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Dementia Discovery Fund, startups are often financed by SV Health Investors, Polaris Partners, OrbiMed. The meaningful sponsors for the fund in investment in the same round are AbbVie Biotech Ventures, Amgen Ventures, SV Health Investors. In the next rounds fund is usually obtained by Illumina Ventures, Amgen Ventures, AbbVie Biotech Ventures.

The overall number of key employees were 3.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AlphaX Partners Beijing, Beijing, China
Bridge Link Capital England, London, United Kingdom
Chengyu Touzi Youxian Gongsi -
Dolik Ventures New York, New York, United States
Grupo Logistico Andreani -
HP Capital California, Culver City, United States
Latitud Brazil, São Paulo, Sao Paulo
SP Acquisitions New York, New York, United States
United Education Company Al Asimah, Al Kuwayt, Kuwait

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Transine Therapeutics

Life Science
$6M31 May 2022 Cambridge, England, United Kingdom


$80M02 Dec 2021 London, England, United Kingdom


$9M23 Nov 2021 London, England, United Kingdom

Nitrome Biosciences

Health Care
$7M02 Nov 2021 Jackson, Mississippi, United States

Transine Therapeutics

Life Science
$12M01 Jun 2021 Cambridge, England, United Kingdom

Therini Bio

Health Care
$17M10 May 2021 San Francisco, California, United States

Cumulus Neuroscience

$8M04 May 2021 Belfast, Northern Ireland, United Kingdom

Alchemab Therapeutics

$82M15 Apr 2021 London, England, United Kingdom


Clinical Trials
Health Care
Health Diagnostics
Medical Device
$8M08 Dec 2020 Belfast, Northern Ireland, United Kingdom
Alchemab Therapeutics Raises £60M in Series A Financing

– Alchemab Therapeutics from Cambridge, England, UK develops a platform that enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires.
– The company raised £60m in Series A funding.
– The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
– The new investment will be used to advance the company’s target-agnostic drug discovery platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Dementia Discovery Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: